SERTAD2

Summary

SERTAD2 (SERTA domain containing 2, HGNC:30784) is a protein-coding gene on chromosome 2p14, encoding SERTA domain-containing protein 2 (Q14140). Acts at E2F-responsive promoters as coregulator to integrate signals provided by PHD- and/or bromodomain-containing transcription factors.

Predicted to enable transcription coactivator activity. Acts upstream of or within negative regulation of cell growth. Located in cytosol and nucleoplasm.

Source: NCBI Gene 9792 — RefSeq curated summary.

At a glance

• GWAS associations: 38
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_014755

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30784
Approved symbol	SERTAD2
Name	SERTA domain containing 2
Location	2p14
Locus type	gene with protein product
Status	Approved
Aliases	TRIP-Br2, KIAA0127, Sei-2
Ensembl gene	ENSG00000179833
Ensembl biotype	protein_coding
OMIM	617851
Entrez	9792

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000313349, ENST00000476805, ENST00000608423, ENST00000859819, ENST00000923255, ENST00000958074

RefSeq mRNA: 1 — MANE Select: NM_014755 NM_014755

CCDS: CCDS33210

Canonical transcript exons

ENST00000313349 — 2 exons

Exon	Start	End
ENSE00001251280	64631621	64636875
ENSE00001406689	64653620	64653913

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 98.46.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.3644 / max 470.3487, expressed in 1814 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
28766	25.8684	1801
28774	6.7208	1595
28765	4.5252	1502
28773	0.7807	559
28775	0.5379	294
28772	0.4870	264
28776	0.2495	119
28767	0.1949	86

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	98.46	gold quality
trabecular bone tissue	UBERON:0002483	96.76	gold quality
esophagus squamous epithelium	UBERON:0006920	96.62	gold quality
buccal mucosa cell	CL:0002336	95.84	gold quality
squamous epithelium	UBERON:0006914	95.73	gold quality
amniotic fluid	UBERON:0000173	95.65	gold quality
cervix squamous epithelium	UBERON:0006922	95.21	gold quality
epithelium of esophagus	UBERON:0001976	95.15	gold quality
gingival epithelium	UBERON:0001949	94.39	gold quality
skin of hip	UBERON:0001554	94.17	gold quality
mammalian vulva	UBERON:0000997	94.13	gold quality
gingiva	UBERON:0001828	93.97	gold quality
tibia	UBERON:0000979	93.87	gold quality
upper leg skin	UBERON:0004262	93.86	gold quality
bone element	UBERON:0001474	93.83	gold quality
penis	UBERON:0000989	93.17	gold quality
bone marrow	UBERON:0002371	92.92	gold quality
oral cavity	UBERON:0000167	92.70	gold quality
thymus	UBERON:0002370	92.54	gold quality
lower esophagus mucosa	UBERON:0035834	92.39	gold quality
pharyngeal mucosa	UBERON:0000355	92.06	gold quality
synovial joint	UBERON:0002217	92.05	gold quality
bronchial epithelial cell	CL:0002328	91.77	gold quality
epithelium of nasopharynx	UBERON:0001951	91.59	gold quality
nasopharynx	UBERON:0001728	91.57	gold quality
hair follicle	UBERON:0002073	91.57	gold quality
visceral pleura	UBERON:0002401	91.56	gold quality
sperm	CL:0000019	91.22	gold quality
parotid gland	UBERON:0001831	91.02	gold quality
tendon of biceps brachii	UBERON:0008188	90.42	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.83
E-MTAB-9801	yes	7.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

328 targeting SERTAD2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-32-5P	99.98	75.21	1964

Literature-anchored findings (GeneRIF, showing 4)

• CRM1-mediated nuclear export may be required for the proper execution of ubiquitin-proteasome-dependent degradation of TRIP-Br2 (PMID:18316374)
• TRIP-Br2 is frequently overexpressed in both cancer cell lines and multiple human tumors. (PMID:19152710)
• TRIP-Br2, modulates fat storage through simultaneous regulation of lipolysis, thermogenesis and oxidative metabolism. (PMID:23291629)
• REV1 promotes lung tumorigenesis by activating the Rad18/SERTAD2 axis. (PMID:35115490)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	sertad2b	ENSDARG00000055530
mus_musculus	Sertad2	ENSMUSG00000049800
rattus_norvegicus	Sertad2	ENSRNOG00000005393
drosophila_melanogaster	tara	FBGN0040071

Paralogs (1): CDCA4 (ENSG00000170779)

Protein

Protein identifiers

SERTA domain-containing protein 2 — Q14140 (reviewed: Q14140)

Alternative names: Transcriptional regulator interacting with the PHD-bromodomain 2

All UniProt accessions (1): Q14140

UniProt curated annotations — full annotation on UniProt →

Function. Acts at E2F-responsive promoters as coregulator to integrate signals provided by PHD- and/or bromodomain-containing transcription factors. May act as coactivator as well as corepressor of E2F1-TFDP1 and E2F4-TFDP1 complexes on E2F consensus binding sites, which would activate or inhibit E2F-target genes expression. Modulates fat storage by down-regulating the expression of key genes involved in adipocyte lipolysis, thermogenesis and oxidative metabolism.

Subunit / interactions. Interacts with XPO1; which mediates nuclear export. Interacts with TFDP1; modulates transactivation activity of TFDP1/E2F complexes.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in adipose tissue.

Post-translational modifications. Polyubiquitinated, which promotes proteasomal degradation.

RefSeq proteins (1): NP_055570* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009263	SERTA_dom	Domain
IPR052262	E2F-SERTA_domain_protein	Family

Pfam: PF06031

UniProt features (12 total): mutagenesis site 3, region of interest 3, compositionally biased region 3, chain 1, domain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14140-F1	60.95	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (3):

Position	Phenotype
241	slight resistance to proteasomal degradation, no effect on the interaction with xpo1 neither on nuclear export.
243	slight decrease of interaction with xpo1 and resistance to proteasomal degradation, no effect on nuclear export.
238	abolishes the interaction with xpo1 as well as the nuclear export and the subsequent proteasomal degradation.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 312 (showing top): TGCACTT_MIR519C_MIR519B_MIR519A, chr2p14, TTTGTAG_MIR520D, ATACCTC_MIR202, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, AAGCCAT_MIR135A_MIR135B, GEORGES_CELL_CYCLE_MIR192_TARGETS, GOBP_GROWTH, IVANOVA_HEMATOPOIESIS_MATURE_CELL, TATTATA_MIR374, GENTILE_RESPONSE_CLUSTER_D3, CTATGCA_MIR153, GTGCCTT_MIR506, BLALOCK_ALZHEIMERS_DISEASE_UP, GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP

GO Biological Process (2): negative regulation of cell growth (GO:0030308), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (2): transcription coactivator activity (GO:0003713), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

568 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SERTAD2	SERTAD3	Q9UJW9	629
SERTAD2	SERTAD1	Q9UHV2	573
SERTAD2	SERTAD4	Q9NUC0	549
SERTAD2	E2F1	Q01094	525
SERTAD2	XPO1	O14980	472
SERTAD2	CDK4	P11802	451
SERTAD2	HRCT1	Q6UXD1	447
SERTAD2	C15orf40	Q8WUR7	433
SERTAD2	KLF15	Q9UIH9	424
SERTAD2	PROSER2	Q86WR7	415
SERTAD2	CDC42EP4	Q9H3Q1	411
SERTAD2	AFTPH	Q6ULP2	406
SERTAD2	CEP68	Q76N32	371
SERTAD2	FAM81A	Q8TBF8	359
SERTAD2	WDPCP	O95876	357

IntAct

67 interactions, top by confidence:

A	B	Type	Score
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
PPP2R2D	YEATS4	psi-mi:“MI:0914”(association)	0.730
PPP2R2B	MYO9A	psi-mi:“MI:0914”(association)	0.640
SERTAD2	ZNF524	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	HELLS	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	PARVG	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	IGFN1	psi-mi:“MI:0915”(physical association)	0.560
PLA2G6	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	TNS2	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	STRA8	psi-mi:“MI:0915”(physical association)	0.560
PRKAB2	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	PIK3R3	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	ESPNL	psi-mi:“MI:0915”(physical association)	0.560
ZSCAN22	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
ATG12	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
CKS1B	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	CTNNA3	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	ZNF581	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	KAT5	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	AIRIM	psi-mi:“MI:0915”(physical association)	0.560
SERTAD2	PPP2R1A	psi-mi:“MI:0914”(association)	0.530
PPP2R1A	ENSA	psi-mi:“MI:0914”(association)	0.530
PPP2R2B	A2ML1	psi-mi:“MI:0914”(association)	0.350
SERTAD2	PPP2R1B	psi-mi:“MI:0914”(association)	0.350
HAPLN3	VWA8	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
PPP2R2C	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
PPP2R2D	MAST4	psi-mi:“MI:0914”(association)	0.350
ZNF524	SERTAD2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (44): SERTAD2 (Affinity Capture-RNA), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid), SERTAD2 (Two-hybrid)

ESM2 similar proteins: A1YF19, A2T767, B0K035, F1RCE7, F7BHS0, O95997, P0DPK0, P23999, P97613, Q08B36, Q08BD8, Q09HN1, Q0VA20, Q14140, Q2KHM9, Q2QD14, Q2QD15, Q2T9X8, Q2WG80, Q3SZY3, Q3UHI0, Q3V1H1, Q5R7F8, Q5RBY6, Q5RKG1, Q5XG16, Q5ZJU5, Q6A000, Q6AYH4, Q6DF94, Q7SXC6, Q8BHE0, Q8BHZ5, Q8C804, Q8N0Z3, Q8QGU6, Q8R080, Q8WWK9, Q96C57, Q96FF9

Diamond homologs: Q14140, Q9BXL8, Q9JJG5, Q9JL10, Q9UHV2, Q9CWM2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cell Cycle	5	10.0×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

395 predictions. Top by Δscore:

Variant	Effect	Δscore
2:64636871:TATAT:T	acceptor_gain	1.0000
2:64636872:ATAT:A	acceptor_gain	1.0000
2:64636873:TAT:T	acceptor_gain	1.0000
2:64636874:AT:A	acceptor_gain	1.0000
2:64636875:TCTGC:T	acceptor_loss	1.0000
2:64636876:C:CC	acceptor_gain	1.0000
2:64636877:T:A	acceptor_loss	1.0000
2:64653615:CTTA:C	donor_loss	1.0000
2:64653616:TTA:T	donor_loss	1.0000
2:64653617:TA:T	donor_loss	1.0000
2:64653618:A:AC	donor_gain	1.0000
2:64653618:A:T	donor_loss	1.0000
2:64653619:C:CC	donor_gain	1.0000
2:64653619:CCA:C	donor_gain	1.0000
2:64636879:C:CT	acceptor_gain	0.9900
2:64653618:AC:A	donor_gain	0.9900
2:64653619:CC:C	donor_gain	0.9900
2:64653619:CCACA:C	donor_gain	0.9900
2:64636880:A:T	acceptor_gain	0.9800
2:64653616:TTAC:T	donor_gain	0.9800
2:64653617:TACC:T	donor_gain	0.9800
2:64653618:ACCA:A	donor_gain	0.9800
2:64653619:CCAC:C	donor_gain	0.9800
2:64653683:C:CA	donor_gain	0.9700
2:64636874:ATCT:A	acceptor_gain	0.9600
2:64639526:ATTG:A	donor_gain	0.9600
2:64636873:TATC:T	acceptor_gain	0.9500
2:64636875:TCTG:T	acceptor_gain	0.9500
2:64636876:CTGC:C	acceptor_gain	0.9500
2:64653631:C:CT	donor_gain	0.9500

AlphaMissense

2060 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:64635940:A:G	L311P	1.000
2:64635940:A:T	L311H	1.000
2:64635952:A:T	I307N	1.000
2:64635961:A:G	L304P	1.000
2:64635961:A:T	L304Q	1.000
2:64636684:A:T	V63D	1.000
2:64636738:A:G	L45P	1.000
2:64636762:C:G	R37P	1.000
2:64636763:G:T	R37S	1.000
2:64635935:C:A	G313W	0.999
2:64635940:A:C	L311R	0.999
2:64635948:C:A	M308I	0.999
2:64635948:C:G	M308I	0.999
2:64635948:C:T	M308I	0.999
2:64635949:A:C	M308R	0.999
2:64635949:A:T	M308K	0.999
2:64635952:A:C	I307S	0.999
2:64635952:A:G	I307T	0.999
2:64635958:T:A	D305V	0.999
2:64635961:A:C	L304R	0.999
2:64636117:T:A	D252V	0.999
2:64636117:T:C	D252G	0.999
2:64636117:T:G	D252A	0.999
2:64636118:C:G	D252H	0.999
2:64636120:A:C	I251S	0.999
2:64636120:A:T	I251N	0.999
2:64636123:T:A	D250V	0.999
2:64636124:C:G	D250H	0.999
2:64636128:A:C	F248L	0.999
2:64636128:A:T	F248L	0.999

dbSNP variants (sampled 300 via entrez): RS1000051080 (2:64654064 GCCGGCCGCGGCCGC>G), RS1000203789 (2:64651789 G>A), RS1000463924 (2:64639134 A>G), RS1000487416 (2:64643702 A>G), RS1000595582 (2:64653677 G>A,C), RS1000653750 (2:64646260 C>T), RS1000665508 (2:64652106 T>C), RS1000818398 (2:64655315 C>G), RS1000898844 (2:64632464 G>A), RS1000946412 (2:64653476 C>T), RS1001006285 (2:64634613 G>A,C), RS1001048152 (2:64650092 GT>G), RS1001209253 (2:64640396 T>A,C), RS1001532288 (2:64645182 C>T), RS1001583066 (2:64645395 A>G)

Disease associations

OMIM: gene MIM:617851 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

38 associations (top):

Study	Trait	p-value
GCST001525_10	Visceral fat	5.000000e-06
GCST004602_87	Mean corpuscular volume	5.000000e-11
GCST004609_139	Monocyte percentage of white cells	9.000000e-10
GCST004621_51	Red cell distribution width	3.000000e-18
GCST004630_28	Mean corpuscular hemoglobin	3.000000e-13
GCST006011_95	Mean corpuscular volume	3.000000e-08
GCST006192_40	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	7.000000e-09
GCST006804_45	Red cell distribution width	7.000000e-13
GCST006979_6	Heel bone mineral density	3.000000e-12
GCST009312_3	Antisaccade task score	1.000000e-07
GCST010204_167	Low density lipoprotein cholesterol levels	8.000000e-09
GCST010243_246	Apolipoprotein B levels	9.000000e-10
GCST010245_21	LDL cholesterol levels	3.000000e-09
GCST010346_35	TPE interval (resting)	8.000000e-12
GCST010346_57	TPE interval (resting)	2.000000e-08
GCST010796_694	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_695	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_696	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-08
GCST010796_697	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST012490_195	Femur bone mineral density x serum urate levels interaction	9.000000e-10
GCST012490_325	Femur bone mineral density x serum urate levels interaction	2.000000e-09
GCST90002390_361	Mean corpuscular hemoglobin	2.000000e-15
GCST90002390_362	Mean corpuscular hemoglobin	1.000000e-16
GCST90002392_202	Mean corpuscular volume	1.000000e-12
GCST90002392_203	Mean corpuscular volume	2.000000e-13
GCST90002393_189	Monocyte count	2.000000e-11
GCST90002394_119	Monocyte percentage of white cells	2.000000e-18
GCST90002396_211	Mean reticulocyte volume	6.000000e-11
GCST90002397_803	Mean spheric corpuscular volume	4.000000e-15
GCST90002397_804	Mean spheric corpuscular volume	1.000000e-09

EFO canonical traits (19, from GWAS)

EFO ID	Trait name
EFO:0007989	monocyte percentage of leukocytes
EFO:0009188	Red cell distribution width
EFO:0004527	mean corpuscular hemoglobin
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0009270	heel bone mineral density
EFO:0007969	cognitive inhibition measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004644	TPE interval measurement
EFO:0004327	electrocardiography
EFO:0004531	urate measurement
EFO:0005091	monocyte count
EFO:0010701	mean reticulocyte volume
EFO:0007985	platelet crit
EFO:0004305	erythrocyte count
EFO:0007986	reticulocyte count
EFO:0004533	alkaline phosphatase measurement
EFO:0004532	serum gamma-glutamyl transferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression	6
Tetrachlorodibenzodioxin	affects expression, affects cotreatment, increases expression	6
sodium arsenite	increases expression, affects cotreatment, increases abundance	2
cobaltous chloride	increases expression, decreases reaction	2
Arsenic Trioxide	decreases expression, increases expression	2
Acetaminophen	increases expression	2
Cisplatin	increases expression, decreases expression, affects cotreatment	2
Estradiol	increases expression, affects cotreatment, decreases expression	2
Formaldehyde	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Valproic Acid	affects cotreatment, increases expression, decreases methylation	2
Aflatoxin B1	increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
dicrotophos	increases expression	1
arsenite	affects binding, decreases reaction	1
mono-(2-ethylhexyl)phthalate	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
zinc chloride	decreases reaction, increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
potassium chromate(VI)	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
14-deoxy-11,12-didehydroandrographolide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.